Home Print this page Email this page Small font sizeDefault font sizeIncrease font size
Users Online: 413
Home | About us | Editorial board | Search | Ahead of print | Current issue | Archives | Submit article | Instructions | Subscribe | Contacts | Login 
     

    Article Cited by others

REVIEW ARTICLE

Drug resistance in leishmaniasis: Newer developments

Mohapatra Sarita

Year : 2014| Volume: 4| Issue : 1 | Page no: 4-9

   This article has been cited by
 
1 Evidence for Tissue Toxicity in BALB/c Exposed to a Long-Term Treatment with Oxiranes Compared to Meglumine Antimoniate
Luiz Filipe Gonçalves Oliveira,Franklin Souza-Silva,Léa Cysne-Finkelstein,Kíssila Rabelo,Juliana Fernandes Amorim,Adriana de Souza Azevedo,Saulo Cabral Bourguignon,Vitor Francisco Ferreira,Marciano Viana Paes,Carlos Roberto Alves
BioMed Research International. 2017; 2017: 1
[Pubmed]  [Google Scholar] [DOI]
2 Understanding serine proteases implications on Leishmania spp lifecycle
Carlos Roberto Alves,Raquel Santos de Souza,Karen dos Santos Charret,Luzia Monteiro de Castro Cortes,Matheus Pereira de Sá Silva,Laura Barral Veloso,Luiz Filipe Gonçalves Oliveira,Franklin Souza-Silva
Experimental Parasitology. 2017;
[Pubmed]  [Google Scholar] [DOI]
3 Metal-Based Nanoparticles for the Treatment of Infectious Diseases
Blessing Aderibigbe
Molecules. 2017; 22(8): 1370
[Pubmed]  [Google Scholar] [DOI]
4 MAPK1 of Leishmania donovani interacts and phosphorylates HSP70 and HSP90 subunits of foldosome complex
Pavneet Kaur,Mansi Garg,Antje Hombach-Barrigah,Joachim Clos,Neena Goyal
Scientific Reports. 2017; 7(1)
[Pubmed]  [Google Scholar] [DOI]
5 Ornithine decarboxylase or gamma-glutamylcysteine synthetase overexpression protects Leishmania (Vianna) guyanensis against antimony
Maisa S. Fonseca,Marcelo A. Comini,Bethânia V. Resende,Ana Maria M. Santi,Antônio P. Zoboli,Douglas S. Moreira,Silvane M.F. Murta
Experimental Parasitology. 2017;
[Pubmed]  [Google Scholar] [DOI]
6 Low versus high dose of antimony for American cutaneous leishmaniasis: A randomized controlled blind non-inferiority trial in Rio de Janeiro, Brazil
Mauricio Naoto Saheki,Marcelo Rosandiski Lyra,Sandro Javier Bedoya-Pacheco,Liliane de Fátima Antônio,Maria Inês Fernandes Pimentel,Mariza de Matos Salgueiro,Érica de Camargo Ferreira e Vasconcellos,Sonia Regina Lambert Passos,Ginelza Peres Lima dos Santos,Madelon Novato Ribeiro,Aline Fagundes,Maria de Fátima Madeira,Eliame Mouta-Confort,Mauro Célio de Almeida Marzochi,Cláudia Maria Valete-Rosalino,Armando de Oliveira Schubach,Aric Gregson
PLOS ONE. 2017; 12(5): e0178592
[Pubmed]  [Google Scholar] [DOI]
7 Mahanine exerts in vitro and in vivo antileishmanial activity by modulation of redox homeostasis
Saptarshi Roy,Devawati Dutta,Eswara M. Satyavarapu,Pawan K. Yadav,Chhabinath Mandal,Susanta Kar,Chitra Mandal
Scientific Reports. 2017; 7(1)
[Pubmed]  [Google Scholar] [DOI]
8 Emergence of visceral leishmaniasis in Sri Lanka: a newly established health threat
H. V. Y. D Siriwardana,P. Karunanayake,L. Goonerathne,N. D. Karunaweera
Pathogens and Global Health. 2017; : 1
[Pubmed]  [Google Scholar] [DOI]
9 Visceral Leishmaniasis: An Update and Literature Review
Abdollah Karimi,Abdolvahab Alborzi,Ali Amanati
Archives of Pediatric Infectious Diseases. 2016; In Press(In Press)
[Pubmed]  [Google Scholar] [DOI]
10 Different Mutations in a P-type ATPase Transporter in Leishmania Parasites are Associated with Cross-resistance to Two Leading Drugs by Distinct Mechanisms
Christopher Fernandez-Prada,Isabel M. Vincent,Marie-Christine Brotherton,Mathew Roberts,Gaétan Roy,Luis Rivas,Philippe Leprohon,Terry K. Smith,Marc Ouellette,Louis Maes
PLOS Neglected Tropical Diseases. 2016; 10(12): e0005171
[Pubmed]  [Google Scholar] [DOI]
11 Mammalian host defense peptides and their implication on combating Leishmania infection
Zahra Abdossamadi,Negar Seyed,Sima Rafati
Cellular Immunology. 2016;
[Pubmed]  [Google Scholar] [DOI]
12 Acetyl shikonin induces IL-12, nitric oxide and ROS to kill intracellular parasite Leishmania donovani in infected hosts
Mamilla R. Charan Raja,Sujatha Srinivasan,Shankar Subramaniam,Narendran Rajendran,Aravind Sivasubramanian,Santanu Kar Mahapatra
RSC Adv.. 2016; 6(66): 61777
[Pubmed]  [Google Scholar] [DOI]
13 Enhanced paromomycin efficacy by solid lipid nanoparticle formulation againstLeishmaniain mice model
M. Heidari-Kharaji,T. Taheri,D. Doroud,S. Habibzadeh,A. Badirzadeh,S. Rafati
Parasite Immunology. 2016;
[Pubmed]  [Google Scholar] [DOI]
14 Comparative Analysis of Cellular Immune Responses in Treated Leishmania Patients and Hamsters against Recombinant Th1 Stimulatory Proteins of Leishmania donovani
Sumit Joshi,Narendra K. Yadav,Keerti Rawat,Chandra Dev P. Tripathi,Anil K. Jaiswal,Prashant Khare,Rati Tandon,Rajendra K. Baharia,Sanchita Das,Reema Gupta,Pramod K. Kushawaha,Shyam Sundar,Amogh A. Sahasrabuddhe,Anuradha Dube
Frontiers in Microbiology. 2016; 7
[Pubmed]  [Google Scholar] [DOI]
15 Leishmaniasis and various immunotherapeutic approaches
Y. TASLIMI,F. ZAHEDIFARD,S. RAFATI
Parasitology. 2016; : 1
[Pubmed]  [Google Scholar] [DOI]
16 The Heme Transport Capacity of LHR1 Determines the Extent of Virulence in Leishmania amazonensis
Rebecca L. Renberg,Xiaojing Yuan,Tamika K. Samuel,Danilo C. Miguel,Iqbal Hamza,Norma W. Andrews,Andrew R. Flannery,Armando Jardim
PLOS Neglected Tropical Diseases. 2015; 9(5): e0003804
[Pubmed]  [Google Scholar] [DOI]
17 Infrared Fluorescent Imaging as a Potent Tool for In Vitro, Ex Vivo and In Vivo Models of Visceral Leishmaniasis
Estefanía Calvo-Álvarez,Kostantinos Stamatakis,Carmen Punzón,Raquel Álvarez-Velilla,Ana Tejería,José Miguel Escudero-Martínez,Yolanda Pérez-Pertejo,Manuel Fresno,Rafael Balaña-Fouce,Rosa M. Reguera,Alain Debrabant
PLOS Neglected Tropical Diseases. 2015; 9(3): e0003666
[Pubmed]  [Google Scholar] [DOI]
18 Immucillins ImmA and ImmH Are Effective and Non-toxic in the Treatment of Experimental Visceral Leishmaniasis
Elisangela Oliveira Freitas,Dirlei Nico,Marcus Vinícius Alves-Silva,Alexandre Morrot,Keith Clinch,Gary B. Evans,Peter C. Tyler,Vern L. Schramm,Clarisa B. Palatnik-de-Sousa,Michael P Pollastri
PLOS Neglected Tropical Diseases. 2015; 9(12): e0004297
[Pubmed]  [Google Scholar] [DOI]
19 New perspectives for leishmaniasis chemotherapy over current anti-leishmanial drugs: a patent landscape
Alice Machado-Silva,Pedro Pires Goulart Guimarães,Carlos Alberto Pereira Tavares,Rubén Dario Sinisterra
Expert Opinion on Therapeutic Patents. 2015; 25(3): 247
[Pubmed]  [Google Scholar] [DOI]
20 Immunogenicity and efficacy of recombinant 78 kDa antigen of Leishmania donovani formulated in various adjuvants against murine visceral leishmaniasis
Rajeev Nagill,Tejinder Kaur,Jyoti Joshi,Sukhbir Kaur
Asian Pacific Journal of Tropical Medicine. 2015; 8(7): 513
[Pubmed]  [Google Scholar] [DOI]
21 In vitro and in vivo antileishmanial properties of a 2-n-propylquinoline hydroxypropyl ß-cyclodextrin formulation and pharmacokinetics via intravenous route
Kaluvu Balaraman,Nashira Campos Vieira,Fathi Moussa,Joël Vacus,Sandrine Cojean,Sébastien Pomel,Christian Bories,Bruno Figadère,Ventikasamy Kesavan,Philippe M. Loiseau
Biomedicine & Pharmacotherapy. 2015; 76: 127
[Pubmed]  [Google Scholar] [DOI]
22 Multidrug Resistance: An Emerging Crisis
Jyoti Tanwar,Shrayanee Das,Zeeshan Fatima,Saif Hameed
Interdisciplinary Perspectives on Infectious Diseases. 2014; 2014: 1
[Pubmed]  [Google Scholar] [DOI]

 

Read this article